论文信息 - A phase 1b/2a study of safety and efficacy of NT-I7 in combination with anti-PD-L1 (atezolizumab) in patients with anti-PD-1/PD-L1 naïve or relapsed/refractory (R/R) high-risk skin cancers: The phase 1b report. - 字舞流文

A phase 1b/2a study of safety and efficacy of NT-I7 in combination with anti-PD-L1 (atezolizumab) in patients with anti-PD-1/PD-L1 naïve or relapsed/refractory (R/R) high-risk skin cancers: The phase 1b report.

J. Sosman | P. Friedlander | P. Funchain | S. Fling | B. Curti | D. Miller | Jean Fan | S. Ferrando-Martínez | A. Silk | B. Gastman | G. Ansstas | Andreanne M. Lacroix | Y. Xing | Ann-Helen Christensen | Byung Ha Lee | Oanh Nguyen